Understanding Appropriate Treatments to Prevent
and Manage Chemotherapy-Induced
Nausea and Vomiting (CINV)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
Eisai Inc. and Merck & Company

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects of cancer chemotherapy treatments. Risk factors for this condition fall into patient-specific and therapy-specific categories. Factors such as gender, age, anxiety, and alcohol use effect the probability that patients will experience CINV. In addition, treatment schedule, chemotherapy dosage, and drug combination can also put a patient at risk for CINV. As many as 80% of cancer patients suffer from this predictable and preventable condition, and as a result, up to 50% of these patients may delay or even refuse potentially life-saving chemotherapy treatments. Because antiemetic medication has such a high success rate, chemotherapy patients no longer have to accept nausea, vomiting, and a decreased quality of life as an automatic consequence of treating cancer. With the addition of these drugs (either orally or intravenously) to chemotherapy, research shows that CINV has been prevented in as many as 80% of patients who normally experience nausea and vomiting after treatment.

Upon Completion of this activity, participants will be able to:

  • Explore the current guidelines to select antiemetic therapy for patients at risk of developing CINV

  • Analyze the safety and efficacy profiles of antiemetic therapies for patients with CINV

  • Identify the classification of CINV and risk factors associated with its development

  • Assess the clinical advances and appropriate use of antiemetic regimens for CINV and its benefits to improve patient outcomes

  • Discuss overcoming barriers for the prevention and management of CINV, including improving patient education and adherence

Faculty: Aminah Jatoi, MD
Professor, Department of Oncology
Mayo Clinic


Dr. Jatoi has no financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
Eisai Inc. and Merck & Company

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue